FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

ICH Mutagenic Impurities Drug Guidance

FDA posts an International Council for Harmonization-developed guidance entitled M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities ...

latest-news-card-1
FDA General

FDA Spending Bill Will See Veto: White House

The Biden Administration threatens to veto a House spending measure that includes cuts to FDAs budget.

latest-news-card-1
Biologics

Syndax/Incyte Plan BLA for Axatilimab

Syndax Pharmaceuticals and Incyte plan to file by the end of the year a BLA for axatilimab, for use in adult and pediatric patients with chronic graft...

latest-news-card-1
Human Drugs

Horizon Misses on Lupus Phase 2 Endpoint

Horizon Therapeutics says a Phase 2 clinical trial evaluating daxdilimab for treating systemic lupus erythematosus failed to meet its primary endpoint...

Medical Devices

Nesa Medtech Fibroid Mapping App Cleared

FDA clears a Nesa Medtech 510(k) for its Fibroid Mapping Reviewer Application (FMRA), intended for use by physicians to generate a 3D model of the ute...

latest-news-card-1
Human Drugs

FDA OKs Verrica NDA for Molluscum Topical

FDA approves a Verrica Pharmaceuticals NDA for Ycanth (cantharidin) topical solution for treating molluscum contagiosum (molluscum) in adult and pedia...

latest-news-card-1
Medical Devices

Datascope Recalls Cardiosave IntraAortic Pumps

Datascope recalls its Cardiosave Rescue IntraAortic Balloon Pumps because of the potential for an unexpected shutdown of the pump.

latest-news-card-1
Human Drugs

ADC Therapeutics Discontinues Phase 2 Trial

ADC Therapeutics says it is discontinuing its Phase 2 LOTIS-9 clinical trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in certai...

latest-news-card-1
Federal Register

Bufferin NDA Withdrawn by FDA

Federal Register notice: FDA withdraws approval of an NDA for Bufferin (aspirin) tablets because the application holder has failed to file required an...

Biologics

FDA OKs Emergents Anthrax Vaccine

FDA approves an Emergent BioSolutions BLA for Cyfendus (anthrax vaccine adsorbed, adjuvanted) for anthrax post-exposure prophylaxis.